Skip to Content

About

Overview

Many of us in the biotechnology industry are driven by personal connections to disease — whether through a loved one’s struggle or the loss of someone in our community. Genetic, oncological, and immunological diseases not only impact the individuals living with often debilitating and life-threatening symptoms, but also significantly impact their families, friends, and caregivers.

Intellia’s researchers work tirelessly to harness CRISPR-based gene editing technologies for human therapeutic use. In fact, one of Intellia’s co-founders, Jennifer Doudna, along with Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR.

At Intellia, we are humbled to have a hand in making what we believe to be medical history. As a leader in this space, our responsibility and commitment to patients is critical in our pursuit of developing novel, potentially curative therapeutics utilizing CRISPR-based technologies.

More specifically, we are employing a modular gene editing platform to create diverse in vivo and ex vivo therapeutics, spanning a range of disease indications. Guided by this full-spectrum approach, we are committed to making CRISPR-based medicines a reality for people suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Our Mission

Transforming lives of people with severe diseases by developing potentially curative genome editing treatments.

Core Values

Our values are at the heart of our company’s identity and culture.

Management Team

Our leaders bring all the necessary skills and experience from world-leading organizations and embody Intellia’s values — one, explore, disrupt, deliver — to deliver gene editing therapeutics. Our team comprises experts in all aspects of developing human therapeutics, including preclinical research, manufacturing and clinical development.

John Leonard, M.D.

John Leonard, M.D.

President and Chief Executive Officer
James Basta, J.D.

James Basta, J.D.

Executive Vice President, General Counsel and Corporate Secretary
Eliana Clark, Ph.D.

Eliana Clark, Ph.D.

Executive Vice President,
Chief Technical Officer
David Lebwohl, M.D.

David Lebwohl, M.D.

Executive Vice President,
Chief Medical Officer
Derek Hicks

Derek Hicks

Executive Vice President,
Chief Business Officer
Laura Sepp-Lorenzino, Ph.D.

Laura Sepp-Lorenzino, Ph.D.

Executive Vice President,
Chief Scientific Officer
Marika St. Amand

Marika St. Amand

Senior Vice President,
Chief Human Resources Officer
Mary Ferguson, J.D., Ph.D.

Mary Ferguson, J.D., Ph.D.

Senior Vice President,
Head of Intellectual Property
Ian Karp

Ian Karp

Senior Vice President,
Investor Relations and Corporate Communications
Birgit Schultes, Ph.D.

Birgit Schultes, Ph.D.

Senior Vice President,
Head of Cell Therapies
Aron Stein, Ph.D.

Aron Stein, Ph.D.

Senior Vice President, Regulatory Affairs
Kristy Wood, Ph.D.

Kristy Wood, Ph.D.

Senior Vice President,
Technical Operations
Yuanxin Xu, M.D., Ph.D.

Yuanxin Xu, M.D., Ph.D.

Senior Vice President,
Early Development and Translational Medicine

Board of Directors

Industry veterans and experienced investors with demonstrated skills in building leading biotechnology companies.

Frank Verwiel, M.D.

Frank Verwiel, M.D.

Chairman of the Board
Muna Bhanji, R.Ph.

Muna Bhanji, R.Ph.

Independent Director
Bill Chase

Bill Chase

Independent Director
Fred Cohen, M.D., D.Phil, F.A.C.P.

Fred Cohen, M.D., D.Phil, F.A.C.P.

Independent Director
Brian Goff

Brian Goff

Independent Director
Jesse Goodman, M.D.

Jesse Goodman, M.D.

Independent Director
Georgia Keresty, Ph.D., M.P.H.

Georgia Keresty, Ph.D., M.P.H.

Independent Director
John Leonard, M.D.

John Leonard, M.D.

President and CEO, Intellia

Partnering

Intellia is a pioneer in the development of CRISPR genome editing and is focused on rapidly moving transformative therapies towards the clinic. We are proud to count biopharmaceutical companies and leading academic institutions as partners – organizations that share our determination to revolutionize medical science.

We seek strategic collaborators to help unlock the full potential of CRISPR genome editing. We scout for cutting-edge technologies that advance the application of CRISPR for human therapeutics and our genome editing platforms, including:

  • Genome modifying technologies
  • Recombination and DNA repair technologies
  • RNA therapeutic technologies
  • Therapeutic delivery of nucleic acids or ribonucleoproteins – viral and chemical
  • Engineered immune cell technologies
  • Novel target identification

Our Partners

Partner
Spotlight

Intellia and ReCode Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

More